



Attorney Docket No.: 01948-056001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Terry B. Strom et al.  
Serial No. : 09/855,313  
Filed : May 14, 2001  
Title : COMPOSITIONS AND METHODS FOR ACHIEVING IMMUNE  
SUPPRESSION

Art Unit : 1645  
Examiner : Unknown

SEP 1 2003

Commissioner for Patents  
Washington, D.C. 20231

**COPY**

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

This statement is being filed before the receipt of a first Office action on the merits.  
Please apply any charges to Deposit Account No. 06-1050 referencing 01948-056001.

Respectfully submitted,

Date: April 8, 2002

Lee Crews, Ph.D.  
Reg. No. 43,567

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20416273.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

April 8, 2002

Signature

Typed or Printed Name of Person Signing Certificate

DEBORAH R. NAST

SEP 15 2003

Sheet 1 of 3

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
01948-056001Application No.  
09/855,313**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Terry B. Strom, et al.Filing Date  
May 14, 2001Group Art Unit  
1645**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,116,964	May 26, 1992	Capon, et al			
	AB	5,552,303	Sept. 3, 1996	Grabstein, et al			
	AC	5,574,138	Nov. 12, 1996	Grabstein, et al			
	AD	5,707,616	Jan. 13, 1998	Grabstein, et al			
	AE	5,747,024	May 5, 1998	Grabstein, et al			
	AF	5,892,001	Apr. 6, 1999	Grabstein, et al			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AG	WO 88/07089	22 Sept 1988	WIPO				
	AH	WO 93/08207	29 Apr 1993	WIPO				
	AI	WO 93/19770	14 Oct 1993	WIPO				
	AJ	WO 94/04180	3 Mar 1994	WIPO				
	AK	WO 94/04570	3 Mar 1994	WIPO				
	AL	WO 94/17773	18 Aug 1994	WIPO				
	AM	WO 95/06480	9 Mar 1995	WIPO				
	AN	WO 95/06481	9 Mar 1995	WIPO				
	AO	WO 95/06666	9 Mar 1995	WIPO				
	AP	WO 95/27722	19 Oct 1995	WIPO				
	AQ	WO 95/28957	2 Nov 1995	WIPO				
	AR	WO 96/16665	6 Jun 1996	WIPO				
	AS	WO 96/23071	1 Aug 1996	WIPO				
	AT	WO 96/26274	29 Aug 1996	WIPO				
	AU	WO 96/40246	19 Dec 1996	WIPO				
	AV	WO 97/17446	15 May 1997	WIPO				
	AW	WO 97/20063	5 Jun 1997	WIPO				
	AX	WO 97/22256	26 Jun 1997	WIPO				

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

01948-056001

Application No.

09/855,313

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant

Terry B. Strom, et al.

Filing Date

May 14, 2001

Group Art Unit

1645

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AY	WO 97/26000	24 Jul 1997	WIPO				
	AZ	WO 97/34633	25 Sep 1997	WIPO				
	AAA	WO 98/01145	15 Jan 1998	WIPO				
	ABB	WO 98/52606	26 Nov 1998	WIPO				
	ACC	WO 98/56417	17 Dec 1998	WIPO				
	ADD	WO 98/58672	30 Dec 1998	WIPO				
	AEE	WO 99/00143	7 Jan 1999	WIPO				
	AFF	WO 99/12566	18 Mar 1999	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AGG	Lin, et al. <i>The Role of Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine Pleiotropy and Redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.</i> Immunity, 2:331-339 (Apr. 1995).
	AHH	Morrison, et al. <i>Structural Determinants of Human IgG Function.</i> The Immunologist 2(4):119-124 (1994).
	AII	Brekke, et al. <i>Structure-Function Relationships of Human IgG.</i> The Immunologist 2(4):125-130 (1994).
	AJJ	Pettit, et al. <i>Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling.</i> The Journal of Biological Chemistry 272(4): 2312-2318 (1997).
	AKK	Stevens, et al. <i>Interleukin-15 signal, T84 colonic epithelial cells in the absence of the interleukin-2 receptor <math>\beta</math>-chain.</i> Am. J. Physiol. 272:G1-G8 (1997).
	ALL	Armitage, et al. <i>IL-15 Has Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation.</i> Journal of Immunology 154:483-490 (1995).
	AMM	Chae, et al. <i>Distribution of IL-15 Receptor <math>\alpha</math>-Chains on Human Peripheral Blood Mononuclear Cells and Effect of Immunosuppressive Drugs on Receptor Expression.</i> Journal of Immunology 157:2813-2819 (1996).
	ANN	Moreland, et al. <i>Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein.</i> N. Engl. J. Med 337(3):141-147 (1997).
	AOO	Elliott, et al. <i>Repeated therapy with monoclonal antibody to tumor necrosis factor <math>\alpha</math> (cA2) in patients with rheumatoid arthritis.</i> Lancet 344(8930):1125-1127 (1994).
	APP	Elliott, et al. <i>Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor <math>\alpha</math> (cA2) versus placebo in rheumatoid arthritis.</i> Lancet 344(8930):1105-1110 (1994).
	AQQ	Williams, et al. <i>Successful therapy of collagen-induced arthritis with TNF receptor-<math>\text{IgG}</math> fusion protein and combination with anti-CD4.</i> Immunology 84(3): 433-439 (1995).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

01948-056001

Application No.

09/855,313

**Information Disclosure Statement  
by Applicant**

Use several sheets if necessary)

Applicant

Terry B. Strom, et al.

Filing Date

May 14, 2001

Group Art Unit

1645

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	ARR	Wooley, et al. <i>Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice.</i> Journal of Immunology 151(11):6442-6607 (1993).
	ASS	Vey, et al. <i>IFN-<math>\gamma</math> and 1,25(OH)<math>_2</math>D<math>_3</math> Induce on THP-1 Cells Distinct Patterns of Cell Surface Antigen Expression, Cytokine Production, and Responsiveness to Contact with Activated T Cells.</i> Journal of Immunology 149(6):2040-2046 (1992).
	ATT	Courtenay, et al. <i>Immunisation against heterologous type II collagen induces arthritis in mice.</i> Nature 283(5748): 666-668 (1980).
	AUU	Burger, et al. <i>Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synovocytes and fibroblasts upon direct contact with stimulated T Lymphocytes.</i> Arthritis & Rheumatism 41(10):1748-1759 (1998).
	AVV	Kim, et al. <i>Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc<math>\gamma</math>2a Protein Blocks Delayed-Type Hypersensitivity.</i> Journal of Immunology 160:5742-5748 (1998).
	AWW	Li, et al. <i>Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis.</i> Journal of Immunology 163:2500-2507 (1999).
	AXX	Kim, et al. <i>Targeting the IL-15 Receptor with an Antagonist IL-15/Fc<math>\gamma</math>2a Protein Blocks DTH and Enhances the Acceptance of Islet Allografts.</i> 17 <sup>th</sup> ASTP (Physicist) Annual Meeting, Chicago, IL May 9-13, 1998 (p. 713).
	AYY	Kirk, et al. <i>Treatment of humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.</i> Nature Medicine 5(6):686-693 (1999).
	AZZ	Nickerson, et al. <i>Prolonged islet allograft acceptance in the absence of interleukin 4 expression.</i> Transplant Immunology 4:81-85 (1996).
	AAAA	Lakkis, et al. <i>Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein.</i> Eur. J. Immunol. 21:2253-2258 (1991).
	ABBB	Li, et al. <i>Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.</i> Nature Medicine 5(11):1298-1302 (1999).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)